Clinical trials in womens cancers

输入项目摘要提供2014财年与此项目相关的研究成果的书面摘要。总结应该清楚地与项目的目的和目的保持一致。描述：主要活动具体目标重大成果，包括重大调查结果、事态发展或结论(正面和负面)主要成果或其他成就2014年，我成为妇女恶意处代理主任。我们的女性癌症诊所终止了一项临床试验(05C0022-贝伐单抗和索拉非尼1期扩大队列)，此前发表了第五篇也是最后一篇手稿，使用了在该试验中收集的数据和标本。我们还完成了三项临床试验(12C0191-卵巢癌的Smac模拟双联试验2期；卵巢癌的07C0058-贝伐珠单抗和索拉非尼2期试验；08C0092-卡铂和奥拉帕布在三组患者中的应用：BRCA突变携带者、高级别浆液性卵巢癌和三阴性乳腺癌)。这些试验的结果和翻译终点在2014年ASCO年会上公布。我们目前有三项临床试验可供应计(11C0022-卡铂和奥拉帕利在女性癌症中的药代动力学；09C0019-贝伐单抗和达沙替尼的1期试验；12C0081-奥拉帕利布和Cederinib在卵巢癌的1-2期试验)。

Enter Project Summary Provide a written summary of the research accomplishments in FY2014 related to this project. The summary should clearly align with the goals and objectives of the project. Describe: major activities specific objectives significant results, including major findings, developments, or conclusions (both positive and negative) key outcomes or other achievements In 2014, I became the Acting Director of the Women's Malignancies Branch. Our Women's Cancer Clinic terminated one clinical trial (05C0022 - Bevacizumab and Sorafenib phase 1 with expansion cohort) after publishing the fifth and final manuscript using data and specimens collected on that trial. We also completed accrual to three clinical trials (12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer; 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer). The outcome and translational endpoints from these trials were presented at the 2014 ASCO Annual Meeting. We currently have three clinical trials open to accrual (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial).